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Abstract Five-lipoxygenase-activating protein (FLAP) is
usually described as an essential protein to activate the
leukotriene (LTs) synthesis via the 5-lipoxygenase pathway. In
the enterocyte model HT29 cl.19 A cell line, 5-lipoxygenase
metabolism was found despite the lack of FLAP expression.
Therefore HT29 cl.19A represents an original mammalian model
to study FLAP-dependent leukotriene synthesis. In FLAP cDNA
transfected HT29 cl.19 A cells, FLAP expression led to an
increase in cyclooxygenase pathway products (mainly PGE2)
without an increase in 5-lipoxygenase metabolism. This increase
in PGE2 synthesis was associated with a cyclooxygenase-2 up-
regulation in comparison to untransfected HT29 cl.19A cells.
These results suggest a possible interaction between the two
major pathways of arachidonic acid metabolism.
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1. Introduction
Arachidonic acid (AA) metabolites named eicosanoids orig-
inate from both cyclooxygenase (COX) and lipoxygenase
(LO) pathways. They are involved in the mediation of various
in£ammatory disorders such as gastrointestinal diseases [1^4].
5-Lipoxygenase (5-LO) catalyzes both the ¢rst step in oxygen-
ation of AA to produce 5(S)-hydroperoxyeicosatetraenoic
acid (5-HPETE) and secondly the production of LTA4 from
5-HPETE. LTA4 is the precursor of potent biological e¡ectors
such as LTB4 or sul¢dopeptidoleukotrienes (LTC4, D4, E4)
[3,4]. A rise in intracellular calcium concentration leads to
the activation and translocation of 5-LO to the nuclear cell
membrane [5^8]. An 18-kDa integral membrane ‘docking’
protein called FLAP (¢ve-lipoxygenase-activating protein), fa-
cilitates the transfer of substrate to 5-LO (AA or 5-HPETE)
resulting in increased LT synthesis [4,6,9^13]. Cyclooxyge-
nases (COX) are the key enzymes which catalyze the commit-
ted step in the formation of prostaglandins (PGs) and throm-
boxanes (TXs) [1]. There are two COX isoenzymes: COX-1
expressed constitutively in most tissues and organs to mediate
house-keeping functions and COX-2 which is de¢ned as the
inducible isoform [14,15] that is normally absent from cells
but expressed transiently in response to growth factors, cyto-
kines, mitogens, etc. [16]. Abnormal COX-2 up-regulation is
involved in the increase in PGE2 synthesis observed in colon
cancer, and this up-regulation is an important early event in
colon carcinogenesis [17].
The permanently di¡erentiated human intestinal epithelial
cell line HT29 cl.19A, deriving from the human undi¡erenti-
ated colonic adenocarcinoma cell line HT29 after treatment
with sodium butyrate [18], is routinely used as an in vitro
model of colon carcinoma [19]. Using HT29 cl.19A cells, we
have demonstrated that the enterocyte could be both target
and producer of AA metabolites through the LO and COX
pathways [20]. These cells possess interesting characteristics:
(i) HT29 cl.19A have abnormal COX-2 expression which was
called ‘constitutive’ and greatly enhanced in the total absence
of fetal bovine serum (FBS) or exogenous inducers [21]. More-
over, this COX-2 up-regulation was associated with a resist-
ance to apoptosis [22]. (ii) They express 5-LO activity (mRNA
and protein) in the absence of FLAP, which was correlated
with a synthesis of metabolites such as 5-HETE, LTB4 and its
isomers [20]. Nevertheless, the absence of FLAP led to limited
metabolite synthesis, especially for LTB4 without peptidoleu-
kotriene synthesis [20]. The absence of FLAP expression has
also been observed in other enterocyte cell lines such as HT29-
18 and HT29-18.C1 cells or in CaCo-2 [23,24]. Therefore, the
HT29 cl.19A cell line represents, by the presence of 5-LO and
LTA4 hydrolase expression, an interesting model for studying
FLAP-dependent LT synthesis. We therefore transfected this
cell line using a FLAP cDNA recombinant mammalian ex-
pression vector.
In positive FLAP expressing transfected clones such as the
HTF C31 cell line, an increase in cyclooxygenase pathway
products such as PGE2 was observed, without any increase
in 5-lipoxygenase pathway metabolites. Moreover, the results
suggested that an up-regulation of COX-2 expression could be
involved in the increase of PGE2 synthesis. This surprising
data could indicate a possible relationship between the two
major AA pathways leading to an increase in prostaglandin
production.
2. Materials and methods
2.1. Chemicals
Cell line HT29 cl.19A was obtained from M. Laboisse (INSERM
U.239, Paris, France). Culture medium was from Eurobio, fetal bo-
vine serum (FBS) was from BioWitaker. Geneticine (G418), trypsin-
EDTA and Superscript Preampli¢cation System were from Gibco-
BRL. RNAzol was from Bioprobe Systems. Taq polymerase was
from Perkin-Elmer. Primers used in polymerase chain reaction
(PCR) were from Appligene. [1-14C]AA, enhanced chemiluminescence
detection system ECL and Hyper¢lm ECP were purchased from
Amersham. Acetylsalicylic acid (Aspirin), indomethacin, calcium ion-
ophore A23187, standards used in the reverse phase high pressure
liquid chromatography (RP-HPLC) and for gas chromatography
mass spectrometry (GC-MS) were all from Sigma. The PGE2 and
LTB4 enzyme immunoassay (EIA), human prostaglandin H syn-
thase-2 monoclonal antibody and REV 5901 were from Cayman.
Complete (anti-protease and EDTA cocktail), T4 DNA ligase, restric-
tion endonucleases and RNase DNase free were from Boehringer-
Mannheim. Nitrocellulose membrane Optiran BA-S83 reinforced
was from Schleicher and Schuell. The pcDNA3(+) vector was from
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Invitrogen. Meloxicam, SC-58125 and L745-337 were a gift from
Dr. M. Pairet (Boehringer-Ingelheim). MK-886 (L-663,536,3-[1-(4-
chlorobenzyl)-3t-butyl-thio-t-isopropyl-indol-2-yl]-2,2-dimethylpropa-
noic acid) was from Calbiochem (La Jolla, CA, USA).
2.2. Cell culture
The HT29 cl.19A cell line was cultured as described before [20] in
Dulbecco’s modi¢ed Eagle’s minimum essential medium supple-
mented with 10% FBS and 4 mM glutamine at 37‡C in a humidi¢ed
6% CO2, 94% room air atmosphere. Cells were routinely screened for
mycoplasma contamination using Chen’s method [25]. Transfected
cell lines were grown in the presence of 600 Wg/ml G418 and used
between passages 15 and 35 after transfection.
2.3. Plasmid construction
The pcDNA3/FLAP cDNA expression plasmid was constructed by
isolating the 843-bp EcoRI fragment containing the entire human
FLAP cDNA from pBluescript SK(3) plasmid (gift from Dr. J.F.
Evans, Merck-Frosst, Center for Therapeutic Research, Canada)
and ligating it into the EcoRI site of pcDNA3(+) expression vector.
This 843-bp fragment contained the open reading frame for human
FLAP gene. This construction placed the cDNA downstream from
and under the transcriptional control of the cytomegalovirus immedi-
ate early response promoter. The sense orientation of this new con-
struction was con¢rmed by restriction endonuclease digestion (BamHI
and BstEII). The pcDNA3(+) expression vector contained the gene-
encoding neomycin resistance which enabled selection for the presence
of this plasmid in mammalian cells using the antibiotic G418.
2.4. Transfection
For electroporation, cells growing in the mid-log phase were trypsi-
nized, washed, pelleted by centrifugation and resuspended in poration
medium (standard culture medium/0.01 M glucose/0.01 M DDT) at a
density of 106 cells/ml. In an electroporation cuvette, 20 Wg of plasmid
(pcDNA3(+) (vector control) or pcDNA3(+)/FLAP cDNA) were
added to 400 Wl of cell suspension and cells were then electroporated,
using Easyject Plus electroporator (Equibio, Angleur, Belgium) set at
0.2 kV and 1050 WF. Then, cells were immediately suspended in 5 ml
of culture medium and 48 h later selection was begun in G418 at 600
Wg/ml. G418 resistant cells were subcultured by trypsinization and
seeded at 5U102 per ml into 130-mm dishes. Isolated G418 resistant
clones (pcDNA3(+) or pcDNA3(+)/FLAP cDNA transfected cells)
were individually transferred, subcultured and ampli¢ed separately
from 96-well dishes to 75-cm2 plastic £asks.
2.5. Human FLAP recombinant baculovirus preparation
As previously described [26], the recombinant transfer vectors pBac
PAK8-FLAP and pBac PAK8-5-LO were constructed by isolating the
EcoRI fragment containing the entire human FLAP cDNA (843 bp)
or the human 5-LO cDNA (2497 bp), respectively, obtained from
pBluescript SK(3) or pUC13 plasmids (gift from J. Evans, Merck-
Frosst Center for Therapeutic Research, Quebec, Canada). As de-
scribed by Clontech, we isolated, puri¢ed, selected (speci¢c RT-PCR
mRNA expesssion and protein Western blotting) and ampli¢ed pure
recombinant baculovirus stocks named, respectively, HFLAP-C1 and
H5LO-C4. As described [26], monolayers of Sf9 cells (8U106) in 175-
cm2 £asks, were inoculated with either H5LO-C4 alone or with
H5LO-C4 and HFLAP-C1 at a multiplicity of infection (M.O.I.) of
¢ve for each virus. Sf9 cells were harvested 48 h post-infection and the
exogenous unlabelled AA (0.5 mM) metabolism was monitored as
described below.
2.6. RT-PCR analysis
Total cellular RNA was isolated with an RNA extraction kit
(RNAzol) [27] and 2 Wg were reverse transcribed into cDNA using
Superscript Preampli¢cation System. Target cDNA was ampli¢ed
under the conditions previously described [20] using 10 Wl of the
reverse transcribed cDNA, 20 pmol of sense (5P^3P) and antisense
(3P^5P) primers (Table 1), 0.2 mM dNTP, MgCl2 and 1 U Taq polym-
erase in 1U PCR bu¡er. The primers were designed to be RNA-
speci¢c [9,20,28^30]. The mixture was overlaid with mineral oil and
ampli¢ed in a thermal cycler (Crocodile II, Appligene) under the
following conditions: (i) 94‡C for 45 s, 62‡C for 45 s, and 72‡C for
1 min, for 30 cycles for 5-LO, FLAP, COX-1; and (ii) 95‡C for 2 min,
for 1 cycle, and 94‡C for 1 min, 60‡C for 1 min, and 72‡C for 1 min,
for 35 cycles for COX-2. With standard negative and positive controls
supplied in the Superscript Preampli¢cation System [20] additional
positive controls were included, using COX-1 and COX-2 cDNAs
(gifts from Dr. T. Hla, Department of Molecular Biology, Holland
Laboratory, Rockville, USA) and FLAP cDNA (gift from Dr. J.F.
Evans, Merck-Frosst Center for Therapeutic Research, Quebec, Can-
ada). PCR products were extracted, visualized and analyzed by elec-
trophoresis [20]. The products resulting from PCR were veri¢ed by
digestion (Table 1), under previously described conditions [20].
2.7. COX-2 Western blot analysis
The cell membrane protein fractions were prepared as described [31]
and 25 Wg of protein was submitted to SDS-polyacrylamide gel (12%)
under reducing conditions (5% L-mercaptoethanol), and electrotrans-
ferred onto nitrocellulose membrane Optiran BA-S83 reinforced NC
0.2 Wm (Schleicher and Schuell). Western blot analyses [32] were car-
ried out using mouse anti-human prostaglandin H synthase-2 mono-
clonal antibody (Cayman Chemical) at 1:1000 dilution for 1 h at
37‡C. Nitrocellulose membrane was incubated with anti-mouse IgG
conjugated to horseradish peroxidase at 1:2000 dilution for 1 h at
37‡C. The signal was revealed using enhanced chemiluminescence de-
tection system ECL, and the membrane was exposed to Hyper¢lm
according to the manufacturer’s instructions (Amersham).
2.8. Subcellular FLAP and 5-LO localization
Freshly trypsinized cells (HT29 cl.19A and HTF C31) were resus-
pended in lysis bu¡er (15 mM Tris-HCl, pH 7.5, 2 mM MgCl2, 1U
Complete solution, a protease and EDTA cocktail). Cells were lyzed
in a dry ice ethanol bath by sonication using a Bioblock Scienti¢c
Vibra Cell 72434 (4U15 s at a power setting of 60%). Sonicates were
centrifuged (12 000Ug, 10 min, 4‡C) and the 12 000Ug pellet was
referred to as the nuclear fraction. The resulting supernatants were
centrifuged (100 000Ug, 60 min, 4‡C). The 100 000Ug supernatant
(referred to as cytosol), the corresponding pellet (referred to as cellu-
lar membranes) and the 12 000Ug pellet were evaluated for protein
concentration by the Lowry method [33] using BSA as a standard.
Each fraction protein (25 Wg) was submitted to SDS-PAGE and im-
munoblot analysis as described for COX-2. Western blots were carried
out using 1:1000 dilution for 1 h at 37‡C of human FLAP polyclonal
rabbit antiserum designated H4TB6 (gift by Dr. P. Vickers, Merck-
Frosst Center for Therapeutic Research, Quebec, Canada) or using
1:1000 dilution for 1 h at 37‡C of human 5-LO polyclonal rabbit
antiserum designated L-859 S8 (gift by Dr. C. Creminon, CEA, Ser-
vice de Pharmacologie et d’Immunologie, DRIPP, Centre d’Etude
Saclay, France). Nitrocellulose membrane was incubated with anti-
rabbit IgG conjugated to horseradish peroxidase at 1:2000 dilution
for 1 h at 37‡C. The signal was revealed using ECL as described
before.
2.9. Immunocytochemistry
Freshly trypsinized cells were seeded onto poly-L-lysine coated glass
coverslips in 6-well plates. For interleukin-1L (IL-1L) dependent pro-
tein expression assay, cells were analyzed 18 h after addition of 10 ng/
ml of IL-1L. For subsequent immuno£uorescent labelling of COX-2
protein, cells were ¢xed with 4% paraformaldehyde in PBS and per-
meabilized with 0.5% Triton X-100 in PBS. The non-speci¢c Fc-bind-
ing sites were blocked by incubation of all coverslips with 3% (w/v)
BSA in PBS, pH 7.4, for 30 min before incubation for 4 h with mouse
anti-human prostaglandin H synthase-2 monoclonal antibody (1:100
in PBS/3% (w/v) BSA), or with mouse preimmune serum (1:100 in
PBS/3% (w/v) BSA) as control. After washing three times with PBS,
cells were labelled for 1 h with FITC-conjugated goat anti-mouse IgG
(1:100 in PBS/3% (w/v) BSA/0.02% (w/v) Evans blue), washed again
and mounted with Immu-mount (Shandon).
2.10. HT 29 cl.19A arachidonic acid metabolism
After three weeks of culture, 55U106 cells were trypsinized, washed
twice with 0.05 M sodium phosphate bu¡er, pH 8.2, resuspended in
500 Wl of the same bu¡er containing 2 mM CaCl2 and 0.5 mM MgCl2
and preincubated for 5 min at 37‡C. Calcium ionophore A23187 (0.5
Wg) and exogenous [1-14C]AA (1.5 WCi, 54 WM) were added in an
ethanolic solution that never exceeded 0.4% and did not a¡ect AA
metabolism. The same experiments were performed (i) on HT29
cl.19A cells; (ii) on HTF C31 cells which is a representative clone
among those expressing FLAP protein; (iii) on HTF C31 cell mono-
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layers preincubated for 8h at 37‡C with 10 ng/ml of IL-1L, a classical
COX-2 gene expression inducer; (iv) on HTF C31 cells preincubated
for 30 min at 37‡C with 10ÿ5 M aspirin or 5U1035 M indomethacin,
non-selective COX-1 and COX-2 inhibitors, with 1035^1038 M me-
loxicam, a selective COX-2 inhibitor, with 1037 M SC-58125 or 1037
M L745-337 which are selective COX-2 inhibitors; (v) on HTF C31
cells preincubated for 5 min with 1036 M MK-886 and 1036 M REV-
5901, LT synthesis inhibitors; (vi) on HTF C1 and HTF C11, two
other positive FLAP expressing clones; (vii) on HT29 cl.19A cells
transfected by pcDNA3(+) (vector control). After 15 min at 37‡C,
the reaction was stopped by the addition of 500 Wl of methanol con-
taining 50 ng/ml of PGB2 as internal standard. Exogenous [1-14C]AA
metabolism was analyzed by RP-HPLC using a tertiary methanol-
acetonitrile-water gradient, as previously described [20,34] and using
5-, 12-, 15-HETEs, PGE2, v6-trans LTB4, v6-trans-12 epi LTB4,
LTB4, LTC4, LTD4, LTE4 and 12-hydroxyheptadecatrienoic acid
(12-HHT) as synthetic standards. Prior RP-HPLC analysis of [1-
14C]AA metabolism, the primary COX pathway derivatives (PGE2,
PGD2, PGB2, TXB2, 6-keto-PGF1K, PGF2K) were identi¢ed by GC-
MS analysis [35] after incubation with 1 mM unlabelled AA.
2.11. Enzyme immunoassay (EIA)
HT29 cl.19A, HTF C31 and vector control cells were cultured as
described and the daily changed medium was centrifuged at 1000Ug
for 5 min at 4‡C, and stored until analysis at 380‡C. The amount of
PGE2 released by cell monolayers was measured by a commercially
available EIA kit according to the manufacturer’s instructions (Cay-
man) using serial dilutions of previously conditioned medium. The
amount of LTB4 produced by cell monolayers was measured by a
commercially available EIA kit according to the manufacturer’s in-
structions (Cayman) using serial dilutions of previously conditioned
medium obtained from unstimulated cells (endogenous AA, no calci-
um ionophore, no calcium) or from stimulated cells incubated for 20
min with calcium ionophore A23187 (1 WM) in the presence of CaCl2
(2 mM), MgCl2 (0.5 mM), using endogenous AA.
3. Results
3.1. RT-PCR analysis
HT29 cl.19A and HTF C31 cells exhibited a positive RT-
PCR signal for COX-1 and COX-2 (data not shown). A
FLAP positive signal corresponding to a speci¢c FLAP
mRNA expression could be detected only in positive FLAP
expressing clone of transfected cells (HTF C1, C11 or C31)
and, as described [20], no positive signal was observed for
untransfected HT29 cl.19A cells or for vector control cells
(Fig. 1). In each case, when we observed a speci¢c band at
the same level as expected and as the ampli¢ed control cDNA,
we veri¢ed the nature of the ampli¢cation products by diges-
tion with speci¢c restriction enzymes (Table 1). In each case,
the same fragments for control cDNAs or for ampli¢cation
products were obtained.
3.2. FLAP expression in baculovirus-Sf9 cell system
The chromatogram pro¢les demonstrated that uninfected
Sf9 cells did not possess any arachidonic acid metabolism.
Sf9 cells coinfected with HFLAP-C1 and H5LO-C4 generated
high levels of both 5-HPETE and LTB4 isomers (data not
shown) compared to cells simply infected with H5LO-C4. In
addition to allowing e⁄cient use of exogenous arachidonic
acid by 5-lipoxygenase, FLAP also a¡ected, as previously de-
scribed [10], the ratio of metabolites synthesized by activation
of LTA4 synthase activity. The ratio of 5-HPETE/LTB4 iso-
mers was approximately 3:1 for cells expressing 5-lipoxyge-
nase alone and 1:1 for cells expressing 5-lipoxygenase and
FLAP (data not shown).
3.3. Transfection of HT29 cl.19A cells
Using RT-PCR analysis, Western blot and RP-HPLC pro-
¢le, 10 positive FLAP expressing clones (named HTF C1, 4, 9,
10, 11, 18, 23, 26, 31, 32) were identi¢ed from 50 initial clones
and expanded (Figs. 1^4). Pure isolated clones of pcDNA3(+)
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Fig. 2. Western blot analysis of FLAP protein. Western blot analy-
sis of COX-2 was carried out using human FLAP polyclonal anti-
body (H4TB6) and anti-mouse IgG conjugated to horseradish per-
oxidase. The signal was revealed using enhanced chemiluminescence
detection system ECL (see Section 2). Lane 1: 25 Wg protein from
HT29 cl.19A cells; lane 2: 25 Wg protein from HTF C31 cells. Posi-
tion of molecular weight ladders is indicated by arrows.
Fig. 1. RT-PCR analysis of FLAP mRNA. Total RNA extracted
from cell monolayers was reverse transcribed, ampli¢ed by PCR us-
ing speci¢c primers and PCR products were analyzed by electropho-
resis on 0.8% agarose gel. Lane 1: Molecular weight ladders: 100
bp DNA ladder; lane 2: negative control: cDNA from chloramphe-
nicol acetyl transferase mRNA with FLAP primers (no band); lane
3: positive control cDNA from chloramphenicol acetyl transferase
with corresponding primers (band at 523 bp); lane 4: cDNA FLAP
positive control (band at 479 bp); lane 5: mRNA from HT29
cl.19A cells; lanes 6^8: mRNA from HTF C1, C11 and C31 cells;
lane 9: mRNA from HT29 cl.19A cells transfected by pcDNA3
(vector control).
Table 1
Oligonucleotides used for ampli¢cation of the mRNA species studied, restriction endonucleases used for PCR product veri¢cation and expected
PCR product size before and after restriction
mRNA
species
5P Primers 3P Primers PCR
products
(bp)
Restriction endonucleases
and fragment sizes
(bp)
COX-1 TGC CCA GCT CCT GGC CCG CCG CTT GTG CAT CAA CAC AGG CGC CTC TTC 303 Tru91 (79 and 224)
COX-2 TTC AAA TGA GAT TGT GGG AAA ATT GCT AGA TCA TCT CTG CCT GAG TAT CTT 305 HhaI (92 and 213)
FLAP ATG GAT CAA GAA ACT GTA CGC ATG AGA AGT AGA GGG GGA GAT G 479 BstEII (181 and 298)
All primers are displayed 5P to 3P.
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transfected cells (vector control) were obtained. Therefore, the
results of our studies using the representative HTF C31 clone
are principally presented here.
3.4. COX-2 protein expression
When HTF C31 cells were analyzed by Western blot, spe-
ci¢c COX-2 protein expression was detected in the form of
triplet at 74-kDa, 72-kDa and 66-kDa bands. At the same
time, we observed two speci¢c COX-2 protein bands at 74
kDa and 66 kDa in HT29 cl.19A cells (Fig. 5). Semi-quanti-
tative evaluation of protein corresponding band by measure-
ment of absorbance with Densylab Ver. 2.05 software (Bio-
probe system) showed that HTF C31 clone synthesized about
2.5^4.5 times more protein than untransfected cells, and that
the 74-kDa band was the major enzyme form produced by
HTF C31 clone.
Results obtained from immunocytochemistry studies con-
ducted on con£uent monolayers showed that no immuno-
£uorescence could be detected in control cells incubated
with bu¡er or mouse preimmune serum (Fig. 6A). Speci¢c
immuno£uorescence could be detected in a few untransfected
HT29 cl.19A and vector control cells (Fig. 6B and C) and was
increased in HTF C31 cells (Fig. 6D). After IL-1L incubation,
the same £uorescence could be detected in a larger portion of
HTF C31 cells (data not shown).
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Fig. 5. Western blot analysis of COX-2 protein. Western blot analy-
sis of COX-2 was carried out using human prostaglandin H syn-
thase-2 monoclonal antibody and anti-mouse IgG conjugated to
horseradish peroxidase. The signal was revealed using enhanced
chemiluminescence detection system ECL (see Section 2). Lane 1:
Puri¢ed sheep COX-2 (3 Wg); lane 2: 25 Wg protein from HT29
cl.19A cells; lane 3: 25 Wg protein from HTF C31 cells. Position of
molecular weight ladders is indicated by arrows.
Fig. 4. Reverse-phase HPLC chromatogram of exogenous [1-
14C]arachidonic acid metabolism. Freshly trypsinized cells (55U106)
HT29 cl.19A cells (A) and HT29 cl.19A pcDNA3 transfected cells
(vector control) (B) were incubated for 15 min at 37‡C in the pres-
ence of [1-14C]AA (1.5 WCi). The metabolites synthesized were ana-
lyzed by RP-HPLC (see Section 2). Metabolites identi¢ed were:
PGE2 (peak 1), LTB4 and 6-trans-LTB4 isomers (peak 2), 12-HHT
(peak 3), compound X (peak 4), 15-HETE (peak 5), 5-HETE (peak
6) and AA (peak 7). The data presented are representative of four
experiments.
Fig. 3. Reverse-phase HPLC chromatogram of exogenous [1-
14C]arachidonic acid metabolism. Freshly trypsinized cells (55U106)
HT29 cl.19A cells (A), HTF C1 cells (B), HTF C11 cells (C) and
HTF C31 cells (D) were incubated for 15 min at 37‡C in the pres-
ence of [1-14C]AA (1.5 WCi, 3 mM). The metabolites synthesized
were analyzed by RP-HPLC (see Section 2). Metabolites identi¢ed
were: PGE2 (peak 1), LTB4 and 6-trans-LTB4 isomers (peak 2), 12-
HHT (peak 3), compound X (peak 4), 15-HETE (peak 5), 5-HETE
(peak 6) and AA (peak 7). The data presented are representative of
four experiments.
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3.5. Subcellular FLAP and 5-LO localization
Western blot analysis showed that FLAP was absent from
all cellular fractions derived from HT29 cl.19A cells (data not
shown). In HTF C31 cells, a positive FLAP signal was prin-
cipally observed in the nuclear fraction and for a slight part in
cytoplasmic fraction (data not shown). A 5-LO positive signal
was observed in the cytoplasmic fraction in both HT29 cl.19A
and HTF C31 cells (data not shown).
3.6. Arachidonic acid metabolites generated by stimulated cells
The HT29 cl.19A cells metabolite pro¢le demonstrated as
previously described [20] that the major 5-LO pathway prod-
ucts were 5-HETE (peak 6, Fig. 3A, Fig. 4A), LTB4 and its
v6-trans-LTB4 isomers which were eluted in an unresolved
broad peak (peak 2, Fig. 3A, Fig. 4A). 15-HETE was also
detected (peak 5, Fig. 3A, Fig. 4A). We also identi¢ed a COX
pathway derivative by the fact that its synthesis largely de-
creased in the presence of COX speci¢c inhibitors. However,
we could not identify this compound as being one of the
primary COX pathway derivatives. This was then named
compound X (peak 4, Fig. 3A, Fig. 4A). The same results
were obtained for vector control pcDNA3(+) transfected cells
(Fig. 4B) and for pcDNA3/FLAP negative clones (no expres-
sion of FLAP mRNA). In the presence of 1035 M aspirin, we
also observed an increase in 15-HETE production.
With HTF C31 cells, no signi¢cant changes were observed
concerning the LO metabolites (Fig. 3D). We did not observe
any increase in 5-LO metabolites. In fact, the most important
event observed for transfected cells was a quantitative and
qualitative di¡erence concerning the COX pathway. We par-
ticularly noticed an increase in PGE2 synthesis which ap-
peared as the major peak (peak 1, Fig. 3D), compound X
(peak 4, Fig. 3D), and 12-HHT (peak 3, Fig. 3D). Similar
pro¢les were observed with other positive FLAP expressing
clones such as HTF C1 or HTF C11 (Fig. 3B and C).
When HTF C31 cells were preincubated with meloxicam,
the inhibition of global COX metabolite synthesis was
100 þ 5% (n = 4) for 1035 M, 58 þ 5% for 1036 M (n = 4),
45 þ 4% for 1037 M (n = 4) and 32 þ 4% for 1038 M (n = 4).
In the presence of 1037 M of SC-58125 or L745-337, inhib-
ition of COX metabolite synthesis was 52 þ 4% (n = 4) and
70 þ 6% (n = 4), respectively (data not shown). When HTF
C31 cell monolayers were preincubated with 10 ng/ml of IL-
1L, the metabolic pro¢le showed a large increase in COX
metabolite synthesis, +105 þ 10% (n = 4), without qualitative
chromatogram pro¢le changes (data not shown).
When HT29 cl.19A or HTF C31 cells were preincubated
with 1036 M MK-886 (n = 4) or 1036 M REV-5901 (n = 4),
we did not observe any changes in COX metabolite synthesis
(data not shown). Under these conditions, we observed a
slight decrease in LTB4 and isomer synthesis in HTF C31
cells.
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Fig. 6. Immunocytochemical detection of COX-2 protein. Subsequent immuno£uorescent labelling of COX-2 protein was done on ¢xed and
permeabilized cell monolayers. The non-speci¢c Fc-binding sites were blocked with 3% (w/v) BSA, before incubation with mouse human prosta-
glandin H synthase-2 monoclonal antibody, or with mouse pre-immune serum as control (A). Cells were labelled with FITC-conjugated goat
anti-mouse IgG and stained with Evans blue. Immuno£uorescence pictures were taken with a Nikon microscope OPTIPHOT-2 (magni¢cation
500U). B: HT29 cl.19A cells; C: HT29 cl.19A pcDNA3 transfected cells (vector control); D: HTF C31 cells.
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3.7. Quanti¢cation of PGE2 by EIA
Table 2 demonstrated a global increase in HTF C31 cell
PGE2 synthesis for each condition tested in comparison
with HT29 cl.19A cells and vector control cells. We especially
demonstrated that FLAP transfection led to a level of PGE2
synthesis very similar to that obtained for IL-1L HT29 cl.19A
stimulated cells.
EIA analysis (Table 2) also demonstrated that unstimulated
HT29 cl.19A cells produced a greater amount of LTB4 than
HTF C31. After calcium ionophore stimulation, LTB4 pro-
duction from endogenous AA in HT29 cl.19A cells was not
signi¢cantly di¡erent from that in HTF C31 cells. However,
the increase in LTB4 production was greater in HTF C31 cells
(+1.05 pg/106 cells) than in HT29 cl.19A cells (0.39 pg/106
cells). A result similar to that of HT29 cl.19A cells was ob-
tained with vector control cells in which the increase in LTB4
production after stimulation was 0.30 pg/106 cells (Table 2).
4. Discussion
Several eicosanoids (PGE2, LTB4, 5-HETE) are increased
in patients su¡ering from in£ammatory bowel diseases and
LTC4, 12-, 15-HETE and TXB2 may be increased in in£amed
tissues compared with normal mucosa [1,2,36,37]. It is now
well established that ulcerative colitis in particular, as well as
Crohn disease predispose to colon cancer [2].
In previous studies concerning the role of enterocytes in AA
metabolism [20], we showed that the HT29 cl.19A cell line,
used as an enterocyte model, could be both a target and
producer of AA metabolites through the LO and COX path-
ways [20], and that this cell line exhibited an unusual constit-
utive COX-2 expression which was linked to resistance to
apoptosis [21,22]. Moreover, this cell line exhibited an active
5-LO pathway, despite the absence of FLAP expression,
which led essentially to the production of 5-HETE, v6-
LTB4 isomers and LTB4 at a low level [20]. This phenomenon
has been reported for a small number of cell lines which were
all derived from intestinal carcinomas [23,24].
In this work, in agreement with a previous report [6], we
found 5-LO to be exclusively located in the cytosolic fraction.
A23187 stimulation enhanced 5-LO enzymatic activity with
increased LTB4 synthesis from endogenous AA (EIA analysis)
or from exogenous [1-14C]AA (RP-HPLC analysis). This re-
sult corresponded to normal 5-LO calcium dependent activ-
ity; nevertheless, the absence of FLAP led to a limited metab-
olite synthesis, especially for LTB4 without peptidoleukotriene
synthesis.
In order to study FLAP-dependent leukotriene synthesis,
we obtained, by transfection with a human FLAP cDNA,
new clones characterized by their speci¢c FLAP mRNA and
protein expression. The capacity of this cDNA to be tran-
scribed and translated into an active FLAP protein was con-
trolled by using the Sf9-baculovirus system during cotransfec-
tion studies with 5-LO: we demonstrated activation of 5-LO
by an increase in 5-HETE and LTB4 isomer synthesis.
In the ¢rst step of our work, we isolated, selected and
ampli¢ed FLAP positive clones as HFT C1, C11 or C31 in
which we expected an increase in 5-LO activity. On the con-
trary, in HTF C1, C11 and particularly in C31 cells, we no-
ticed a surprising COX pathway activation. Several studies
have demonstrated that COX-2, but not COX-1, mRNA
and protein are elevated in human colon cancer [17,38^42],
and authors considered that abnormal COX-2 up-regulation
involved in the increase in PGE2 synthesis observed in colon
cancer was an important early event in the disease process
[41,42]. So, with regard (i) to the AA metabolism studies in
positive FLAP expressing clones, and (ii) to the particular
COX-2 expression in HT29 cl.19A cell line [21,22], we ex-
plored COX-2 expression under various conditions using the
HTF C31 clone (most representative FLAP expressing clone),
in comparison with HT29 cl.19A results.
HTF C31 cells showed a COX-2 mRNA expression asso-
ciated with speci¢c COX-2 protein synthesis demonstrated by
the presence on Western blot of the classically described forms
of COX-2: the 66-kDa form which is the inactive non-glyco-
sylated enzyme and the 72- and 74-kDa forms which repre-
sented the active enzymes, respectively glycosylated 3 and 4
times [43,44]. On the contrary, in HT29 cl.19A cells we ob-
served a lower protein synthesis and the absence of the 72-
kDa form. This was in agreement with immunohistochemistry
studies in which speci¢c COX-2 £uorescence could be detected
in a larger part in HTF C31 than in HT29 cl.19A cells. These
results were also associated with the presence of a more active
AA metabolism, via COX pathway, in HTF C31 clones, in
comparison with HT29 cl.19A cells. We particularly showed a
large increase in PG synthesis with ionophore A23187 stimu-
lated cells. PGE2 EIA measurements of unstimulated (neither
ionophore A23187 nor exogenous AA) cells clearly indicated a
higher level of PGE2 synthesis by the HTF C31 clone corre-
sponding to an increase in COX-2 protein synthesis. The in-
ducible nature of COX-2 expression in HTF C31 clone was
supported by the following arguments. Preincubation with IL-
1L, a COX-2 gene inducer [45], led to a speci¢c increase in
protein synthesis, as shown by immuno£uorescence studies,
associated with an increase in COX-2 metabolites (especially
PGE2), without any qualitative modi¢cation of the chromato-
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Table 2
EIA analysis of PGE2 and LTB4 production
Eicosanoid HT29 cl.19A cells HTF C31 cells Vector control cells
PGE2 (pg/106 cells)
Unstimulated cells 9.0 þ 0.5 17.6 þ 0.7 8.5 þ 0.6
IL-1L 17.0 þ 0.7 24.5 þ 0.8 17.4 þ 0.5
LTB4 (pg/106 cells)
Unstimulated cells 3.55 þ 0.17 2.55 þ 0.19 3.70 þ 0.15
A23187 3.94 þ 0.21 3.60 þ 0.16 4.00 þ 0.20
PGE2 synthesis was evaluated in cell monolayers in the total absence of stimulation by ionophore A23187 and exogenous AA, in the presence or in
the absence of 10 ng/ml IL-1L stimulation. The amount of LTB4 produced by cell monolayers was measured in unstimulated cells (endogenous AA,
no calcium ionophore, no calcium) or from stimulated cells incubated for 20 min with calcium ionophore A23187 (1 WM) (CaCl2, MgCl2,
endogenous AA). Values are expressed as the mean þ S.E. (n = 3 experiments, P6 0.05).
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gram. This could indicate, in association with an inhibitory
e¡ect of meloxicam, SC-58125 or L-745-337, all considered
selective COX-2 inhibitors, that the major part of COX activ-
ity in HTF C31 clone was due to COX-2 activity. Our results
also indicated that FLAP cDNA transfection increased COX-
2 gene transcription but the exact mechanism by which COX-
2 gene expression was increased after FLAP transfection has
not yet been de¢ned.
In this work, we showed that HTF C31 cells exhibited
FLAP expression (mRNA, protein), which is located in the
nuclear fraction, in agreement with a previous report [6].
Moreover, even if unstimulated HTF C31 cells produced
less LTB4 than unstimulated HT29 cl.19A cells, EIA analysis
demonstrated that the presence of FLAP in transfected cells
enhanced LTB4 synthesis after A23187 and calcium stimula-
tion.
Our results showed that simple transfection of cells with
pcDNA3 alone did not modify metabolism in comparison
with untransfected cells. Our results also demonstrated that
FLAP transfection enhanced the COX pathway as observed
in di¡erent positive FLAP expressing clones such as HTF
C31, C1 or C11. Thus, many hypotheses could be suggested
to explain COX-2 activation after FLAP transfection. The
absence of inhibitory e¡ects of both MK-886, which blocks
the AA binding site of FLAP, and REV-5901 which blocks
FLAP-dependent LT synthesis, could rule out COX-2 up-reg-
ulation by a direct FLAP-dependent mechanism. Another hy-
pothesis could be that FLAP-dependent LT synthesis is im-
plicated in increased COX-2 gene expression. This can be
eliminated by EIA LTB4 analysis run on unstimulated mono-
layers in which HT29 cl.19A cells produced more LTB4 than
HTF C31. Thus, no increase in FLAP-dependent LT synthesis
is implicated in COX-2 gene expression. The lesser capacity of
HTF C31 cells to produce LTB4 could be due to an increase
in AA metabolism by the COX-2 pathway.
Taken together, RT-PCR, Western blot, immunochemistry,
RP-HPLC and EIA AA analysis showed that HTF C31 cells
exhibited, under our experimental conditions, a speci¢c in-
crease in COX-2 expression and activity in comparison with
HT29 cl.19A cells. This could constitute a possible interaction
between the major pathways of AA metabolism, acting to
increase eicosanoid synthesis by an unknown mechanism.
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